http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3946319-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9244628bc654403471daf0a8708a39c2 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 |
filingDate | 2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b0aab7900ff33450cebe0286e58d05d |
publicationDate | 2022-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-3946319-A1 |
titleOfInvention | Beta-carboline compounds and use thereof for the non-cytotoxic and immunological treatment of cancer |
abstract | The invention provides a β-carboline compound (an indole-containing compound)able to induce actin network remodeling in cancer cells into actin organized network and use thereof in non-cytotoxic cancer immunotherapy, for enhancing immune checkpoint inhibitor therapy, for activating cancer immune response, for treating or lessening the symptoms of, or preventing the human cancer, alone or in combination with one or more cancer immunotherapeutic agent for simultaneous, separate or sequential administration. |
priorityDate | 2019-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.